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Abstract
Chemokines, small chemotactic cytokines, orchestrate cell migration by binding to their cog-
nate chemokine receptors. While chemokine-mediated stimulation of typical G-protein-coupled
chemokine receptors leads to cell migration, binding of chemokines to atypical chemokine recep-
tors (ACKRs) does not induce canonical signaling. ACKRs are considered important chemokine
scavengers, that can create gradients which help direct cells to sites of inflammation or to their
immunological niches. Synthetic chemokines have been used in the past to study and decode
chemokine-receptor interactions. Characterizing specific chemokine-ACKRs interactions is chal-
lenging because the chemokines bindmultiple receptors; for example, theACKR3 ligandsCXCL12
and CXCL11 bind to the canonical receptors CXCR4 and CXCR3, respectively. Here, we present
the engineering of a chemokine-like chimera, which selectively binds to ACKR3. The addition of a
ybbR13 tag at theC-terminus allows site specific enzymatic labelingwith a plethora of fluorescent
dyes. The chimera is composedof theN-terminus ofCXCL11 and themain body andC-terminus of
CXCL12 and selectively interactswithACKR3with high affinity, while not interferingwith binding
of CXCL11 andCXCL12 to their cognate receptors.We further provide evidence that the chimera
can be used to study ACKR3 function in vivo.
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1 INTRODUCTION
Chemokines and their cognate chemokine receptors constitute the
chemokine system, which principally orchestrates leukocyte traf-
ficking during homeostasis and inflammation. The system is also
involved in development and has a key role in cancer growth and
metastasis.1 Typical pertussis toxin-sensitive chemokine receptors,
members of the rhodopsin like family of G-protein coupled receptors
(GPCRs), activate diverse intracellular signaling cascades and com-
monly trigger cell migration. In addition to the “typical” or “canonical”
receptors, chemokines also bind to atypical chemokine receptors
(ACKRs). ACKRs are heptahelical membrane proteins, structurally
homologous and phylogenetically related to canonical chemokine
Abbreviations: ACKR, atypical chemokine receptor; GPCR, G-protein coupled receptor; HPF, high power field; IMAC, immobilized-metal affinity chromatography;MFI, mean fluorescence
intensity; PFA, paraformaldehyde
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receptors, but do not couple to G-proteins and do not activate the
respective downstream signaling cascades, hence, do not induce
cell migration.2 The main activity of ACKRs is the scavenging of
chemokines, thereby controlling their availability for typical receptors,
modulating, and shaping chemotactic gradients. Growing evidence
indicates that alternative signaling pathways, via arrestin in par-
ticular, may be triggered following chemokine ligation of ACKRs.
Currently four ACKRs have been identified. ACKR3, also known as
CXCR7, binds and scavenges the chemokines CXCL12 and CXCL11.
The receptor can contribute to the overall activity of CXCR4, the
cognate chemokine receptor of CXCL12. Soon after the discovery of
ACKR3 as second receptor for CXCL12, it was shown in Zebrafish
that CXCL12-directed CXCR4-dependent migration of primordial
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germ cell requires ACKR3 expression.3,4 The scavenging acitivity of
ACKR3 expressed on stroma cells is required to maintain CXCL12
gradients for directed migration of the germ cells.4,5 In addition, the
cells of the primordium express CXCR4 and ACKR3 at the anterior
and posterior side, respectively, creating CXCL12 gradients.6,7 During
mouse brain development ACKR3 controls the levels of CXCL12 to
promote the CXCR4-dependent outgrowth of interneurons.8 Under
inflammatory conditions ACKR3 is upregulated at the basal site of
brain microvessel endothelium scavenging perivascular CXCL12,
thereby abolishing the perivascular retention of CXCR4+ leuko-
cytes and indirectly promoting their entry into the parenchyma.9
Using a disseminated xenograft model, we recently reported that
the diffuse large B cell lymphoma Val cells require ACKR3 expres-
sion for organ infiltration. In vitro ACKR3 expression by these cells
was required for efficient CXCL12-induced CXCR4-dependent
chemotaxis.10 Ectopic expression of overexpressed ACKR3 and
CXCR4 was suggested to result in heterodimerization, which altered
CXCR4-dependent signaling.11 Both receptors, ACKR3 and CXCR4,
are broadly expressed on hematopoietic and mesenchymal cells.1,12,13
The second ligand of ACKR3 is CXCL11, an IFN-𝛾 inducible chemokine.
CXCR3 binds CXCL11 with high affinity (apparent Kd ∼ 1 nM)14 and is
expressed on various lymphocytes.1 Targeted gene deletion of ACKR3
revealed a key role of the receptor in development, as deficient mice
are not viable displaying a marked cardiac phenotype with stenotic
defects in heart valves and vessels. Interestingly, the mouse strain
used for target deletion C57BL/6 is deficient in CXCL11, hence
the phenotype was ascribed to the abolished interaction of ACKR3
with CXCL12.15
One chemokine can bind several receptors and a receptor can bind
multiple chemokines.1 Given this promiscuity of the chemokine sys-
tem, delineating the specific activity of a chemokine receptor pair in
vivo is challenging. It is therefore valuable to engineer structurally
related chemokineswhich specifically target a single receptor, in order
to study ligand-receptor interactions in complex biological systems.
About 50 human chemokines have been characterized. They are small
proteins (8–10 kD) with highly diverse primary sequences, but share
structural homology dictated by 4 conserved cysteines forming two
characteristic disulfide bridges. According to the two step binding
model16 the rigid loop (also called N-loop) with an overall basic charge
downstream of the first two cysteines mediates the initial binding to
the negatively chargedN-terminus of the receptors.Whereas the flex-
ible N-terminus of chemokines inserts into the binding pocket of the
receptors triggering conformational changes which translate in intra-
cellular signaling. In line with this, modifications of the N-terminus
often result in altered receptor activation leading to either loss of func-
tion or enhanced potency and/or efficacy. Three beta strands and the
short helix present at the C-terminus of most chemokines harbor gly-
cosaminoglycan (GAG) binding sites for presentation of chemokines
on cell surfaces, which is required for haptotatic migration of cells.17
Binding and retention of chemokines on cell surfaces or the extracel-
lular matrix is critical for the formation of locally confined chemotac-
tic gradients.18 However, the interactions of chemokines with GAGs is
not uniform and can fine-tune the function of chemokines.19 CXCL12𝛼
possesses one GAG binding site in its first 𝛽-strand20,21 and differs
therein from CXCL12𝛽 and particularly CXCL12𝛾 , which harbor addi-
tional GAG binding sites at their extended C-termini.22,23
In solution, CXCL12 can form dimers depending on the environ-
mental conditions, such as pH and heparin.24 Monomeric and dimeric
forms of CXCL12 were shown to bind and to induce signal bias on
CXCR4,wheredimericCXCL12poorly recruits arrestin andessentially
does not stimulate cell migration.25,26 ACKR3 binds preferentially
monomeric CXCL1227 with about 10-fold higher affinity than CXCR4
(apparent Kd for ACKR3 ∼ 0.3 nM).28,29 The affinity of CXCL11, the
second chemokine ligand of ACKR3, is somewhat lower (2–5 nM).29
CXCL11 and CXCL12 share at most 20% of their primary sequences
including the 4 conserved cysteines. The N-termini preceding the
first cysteine of both chemokines have the same length, but share
only the amino acids at position 2 (proline; P, one letter code) and
8 (arginine; R). Currently no crystal structure of ACKR3 is avail-
able, however extensive radiolytic footprinting revealed contact points
between CXCL12 and ACKR3. Comparing the sequences of CXCL11
and CXCL12 with the data from the radiolytic footprinting suggests
that different domains of ACKR3 must be involved in the recognition
of the 2 chemokines.30 A recent study confirmed different modes of
binding of CXCL11 andCXCL12 toACKR3.31 CXCL11 induced a faster
ACKR3 internalization, but slower recycling than CXCL12. Moreover,
the authors suggest that arrestin binding to ACKR3 is not required
for chemokine scavenging.31 The finding somewhat contrasts other
observations where it was shown that CXCL11 and CXCL12 binding
to ACKR3 enhances arrestin recruitment.32–36
A known drawback for the investigations of GPCRs is the paucity
of antibodies which recognize endogenous receptors expressed at
the cell surface. Alternatively, chemokine receptor surface expression
and function was successfully measured with fluorescent labeled
chemokines.10,37–40 The specificity of this approach is limited by the
promiscuity of the chemokine system, in addition chemokines are
internalized through the scavenging activity of atypical receptors.
Nevertheless, fluorescent chemokines can also be used in vivo to
reveal receptor localization and function.41 There are no selective
chemokines for ACKRs because its cognate chemokines bind at least
to one canonical receptor. Here, we describe the engineering of a
novel chimeric chemokine combining CXCL11 and CXCL12, which is a
selective ligand for ACKR3 and, by analogy to CXCL12, is monomeric
and has reduced GAG binding ability. The chimera was in addition
tagged at the C-terminus with an acyl carrier protein tag for site
specific enzymatic labeling with fluorophores.40,42,43 The high affinity
of the chimera for ACKR3 allows to reveal sites of functional ACKR3
expression in vivo.
2 MATERIALS AND METHODS
2.1 Cells
Mouse 300.19 pre-B cells were cultured in B cell medium (RPMI-1640
supplemented with 10% FBS, 1% PenStrep, 1% nonessential amino
acids, 1%Glutamax, and 50𝜇M 𝛽-mercapto ethanol (𝛽-ME)). CEMcells
were cultured in T cell medium (RPMI-1640 supplemented with 10%
FBS, 1% PenStrep, and 1% Glutamax). HeLa cells were maintained in
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high glucose DMEM (4.5 g/l) supplemented with 10% FBS and 1%
PenStrep. All cell culture media and supplements were from Ther-
mofisher. Transient transfections with plasmids containing an inter-
nal ribosomal entry side encoding for chemokine receptors CXCR4,
CXCR3, or ACKR3 and EGFPwere performedwith 500 ngDNA added
to 1 𝜇l Lipofectamine LTX and 0.5 𝜇l PLUS reagent (Thermofisher)
per glass-bottom Petri dish (MatTek). Cells were left overnight and
inspected for GFP expression prior to experimental usage. Bone mar-
row cells from WT and ACKR1-deficient mice were prepared as
described elsewhere.44
2.2 Chemokine expression and purification
Recombinant chemokines were expressed in E. coli as previously
described.42 Briefly, chemokine sequences were preceded by an
enhancer GroE sequence, followed by an 8-H encoding sequence, 2
amino acids (LE), and the enterokinase recognition site (DDDDK).45
When indicated to the C-terminus of the chemokine the ybbR13
(DSLEFIASKLA) sequence was fused to allow site specific labeling
with phosphopantetheinyl transferase.43 Chemokines were purified
from inclusion bodies by immobilized-metal affinity chromatography
(IMAC) and refolded under N2 protection in an arginine containing
buffer (80 mM Tris-Cl (pH 8.5), 100 mM NaCl, 0.8 M arginine, 2 mM
EDTA, 1 mM cysteine, 0.2 mM cystine). After recovery and concentra-
tion the N-terminus was cleaved with enterokinase and chemokines
purified by C18 reverse phase chromatography.
Chemokines were labeled with phosphopantetheinyl transferase
(Sfp) (New England Biolabs), fluorescent labeled CoA.42,46 Briefly,
ybbR13-tagged chemokines (10 𝜇M) were incubated overnight at
room temperature in the dark in 20% glycerol, 100 mM NaCl, 10 mM
MgCl2, 50 mM HEPES, 1 𝜇M Sfp, and 20 𝜇M CoA conjugated fluo-
rophore (Atto565, Alexa647, or Atto700). Labeled chemokines were
purified by reverse phase chromatography.
2.3 Chemokine binding and uptake assay
by flow cytometry
Mouse300.19 pre-B cells expressing eitherACKR3, CXCR4, orCXCR3
were incubated at 4◦C on ice or at 37◦C (5% CO2/humidified air) for
90min inB cellmediumcontaining 50nM fluorescent labeledCXCL11,
CXCL12, or CXCL11_12. Cells were washed once in PBS. To deter-
mine uptake at 37◦C the cells were subjected to a short acidic wash for
1 min at 4◦C to remove surface bound chemokines.47 Surface bound
and internalized chemokines weremeasured by flow cytometry (FACS
Fortessa, BD Biosciences) and analyzed with FlowJo software.
Competition binding assays were performed with mouse pre-B
300.19 cells stably expressing human ACKR3.37 Cells were incubated
at 4◦C for 90 min in RPMI, 1% human pasteurized plasma (PPL, CSL
Behring AG) with 1 nM fluorescent labeled CXCL11_12_Alexa647.
Competitionwas achievedwith increasing concentrations of unlabeled
CXCL11_12, CXCL11 and CXCL12. Cells were washed once with ice
cold PBS containing 2% FBS. Binding of CXCL11_12 Alexa647 was
measured by flow cytometry and quantified using geometric mean
fluorescence intensity (MFI). Unspecific binding was measured using
MFI values from displacement binding assays performedwith parental
300.19 cells.
2.4 Chemokine uptake assay by confocal
microscopy
Uptake of fluorescent labelled chemokines was measured in tran-
siently transfected HeLa cells incubated for 45 min at 37◦C in
OptiMem containing 50 nM CXCL11_Atto565, CXCL12_Atto565,
and CXCL11_12_Atto565. Cells were washed in warm PBS, fixed in
4% paraformaldehyde (PFA) in PBS for 20 min at room temperature,
stained with DAPI (0.1 𝜇g/ml PBS) for 5 min and washed with PBS.
Cells were imaged with a laser scan confocal microscope (Leica SP5)
and images analyzed using Imaris software (Bitplane).
Chemotaxis assays were performed using 48-well modified Boy-
den chambers (AP48, NeuroProbe) as previously described.48 CEM
cells (100,000/well) were allowed to migrate for 90 min at 37◦C in an
incubator (5% CO2) toward increasing concentrations of chemokine
(0.1–100 nM) added to the lower wells through 5 𝜇m pored poly-
carbonate membranes (PVPF, NeuroProbe). Chemotactic assays using
300.19 pre-B cells stably expressing CXCR3 were performed as
described above, in amodified chemotaxis buffer (RPMI supplemented
with 25mMHEPES and 1%PPL). Chemotaxiswas quantified by count-
ing the number of migrated cells per high power field (HPF).48
2.5 In vivo uptake
ACKR3 GFP reporter mice9 were anesthetized and injected i.v. with
150 𝜇l of 6.5 𝜇M CXCL11_12 H25R Gag− Alexa647 in PBS. After
20 min, animals were sacrificed and flushed with PBS by injecting
20 ml PBS in the hearts. The organs were removed and placed in 4%
PFA in PBS overnight at 4◦C with slow agitation. Hearts were placed
in fresh PBS and stored at 4◦C until processing. For tissue processing
the organs were placed into low melting agarose (2%) and sections
of 150 𝜇m were cut with a vibratome (Leica VT1200s) until valves
became visible. Sections were stained with DAPI (0.1 𝜇g/ml) in PBS
for 30 min at RT, washed twice for 30 min with PBS, 1% FCS, 0.1%
TritonX100, and 0.01%NaN3. Tissue sections were imaged with a
laser scan confocal microscope (Leica SP5) and analyzed using Imaris
software (Bitplane).
3 RESULTS
For determining the surface expression and scavenging activity of
ACKR3 a specific endogenous ligand is missing. CXCL11 and CXCL12
both bind to ACKR3, but also to their cognate receptors CXCR3
or CXCR4, respectively, making it difficult to reveal the expression
and function of the atypical receptor in the presence of the canon-
ical receptors. AMD3100 was described as selective inhibitor of
CXCR4, which blocks binding and CXCL12-mediated signaling49,50
and could be used to discriminate between CXCR4 and ACKR3-
dependent CXCL12 internalization. However, at full effective concen-
trations AMD3100 also targets ACKR3.31,51 Binding of CXCL11 to
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CXCR3 can be similarly abolished with small molecule inhibitors, how-
ever, ACKR1 also binds the chemokine potentially obscuring interac-
tionswith ACKR3.1 In order to design a selective ligand for ACKR3, we
hypothesized that a chimeric chemokine composedof domains derived
from CXCL11 and CXCL12 could possess such characteristic. Modi-
fication or truncation of the N-terminus of CXCL12 markedly affects
its affinity for CXCR4.16 Exchange of proline2 with glycine on CXCL12
(P2G-CXCL12) turns the chemokine into an antagonist that binds
CXCR4 with similar affinity as the wild type counterpart, but does not
induce signaling.16,52 To test a possible effect of substitutions at theN-
terminus of CXCL12 for its ability to bind to ACKR3 we took advan-
tage of an in house available fluorescent fusion protein P2G-CXCL12-
YFP, which bound to CXCR4 expressing MDCK cells, and as expected,
did not induce signaling.16,52 However, the fusion protein was read-
ily internalized byMDCK cells transiently expressing ACKR3, suggest-
ing that the substitution of the critical proline at the N-terminus did
not abolish scavenger activity (not shown). On the other hand trunca-
tion of the N-terminus of CXCL12 was reported to markedly reduce
its binding to ACKR3,28 suggesting that the domain plays some role in
chemokine recognition.
3.1 Chimeric construct
Considering that ACKR3 binds CXCL12 and CXCL11, we designed a
chimeric chemokine consisting of the 8 amino acids of the N-terminus
of CXCL11 and the body of CXCL12𝛼 starting with the common
arginine8 preceding the first cysteine9 of the CXC motif (Fig. 1). The
first 𝛽-strand of CXCL12 contains a BBXB (B for basic amino acid and
X any amino acid) motif comprising lysine (K)24, histidine (H)25, and
lysine (K)27 which promotes GAG binding21,53 together with lysine
(K)41 located on the second 𝛽-strand.54 In order to reduce GAG inter-
actions, which could lead to background signals when ACKR3 binding
is imaged in tissues, we substituted these residues by exchanging K24,
K27, and K41 for serine (S) at all positions. Replacing histidine25 with
arginine at the potential dimerization interface was shown to shift
the equilibrium to the monomeric state of CXCL12𝛼,24 which is the
favored state for the chemokine to bind ACKR3.27 Figure 1 depicts
the modifications in the first and second 𝛽-strand. We fused a tag for
site specific enzymatic labeling to lysine (K)68 located at the extreme
C-terminus of CXCL12𝛼, based on the notion that modifications of the
C-terminus have minor effects on chemokine receptor binding.40,42
We chose a short peptide tag for orthogonal protein labeling with
phosphopantetheinyl transferase, which was fused to the palindrome
sequence for BsiW1 (encoding for RT) allowing cassette cloning of
chemokines. The 11 amino acid-long ybbR13 sequence (DSLEFI-
ASKLA) was derived from B. Subtilis peptidyl carrier protein and is
targeted by phosphopantetheinyl transferase Sfp from B. subtilis.43,55
The affinity of the tag for the Sfp enzyme is 123 𝜇M permitting an
efficient modification of the serine residue at position 2 of the ybbR13
sequence with conjugated CoA as substrate.43,56 We selected the
ybbR13sequence because this consensus sequence is less hydropho-
bic comparedwith other motives and has a reasonably high affinity for
the B. Subtilis enzyme Sfp.43,57 Fusing more hydrophobic sequences
with higher affinity for Sfp to the C-termini of chemokines caused
their tendency to aggregate (not shown). The relative insensitivity
of phosphopantethenyl transferases for modifications at the free
sulfhydryl group of CoA allows to site specific label tagged chemokines
with almost any low molecular weight fluorophore.42,46 The full name
of the chimeric chemokine, CXCL11_12 H25R Gag− ybb13, recon-
ciles all these features, for convenience, we use here the short form
CXCL11_12 followed by the fluorophore linked to the ybbR13 tag.
We expressed CXCL11_12 in E.Coli with an His-tag and the
enterokinase consensus sequence at the N-terminus42 and isolated
the chimera from inclusion bodies by IMAC. After folding and purifi-
cation by hydrophobic interaction chromatography the N-terminus
was removed with enterokinase and the cleaved product purified by
reverse phase HPLC. The final product migrated as single band on
SDS-PAGE. Mass spectrometry revealed an average mass of 9361.98
which is in good agreement with the calculated average Mw 9366.95
of CXCL11_12 containing two disulfide bridges.
3.2 Binding and specific uptake of CXCL11_12
First, we tested the binding of CXCL11, CXCL12, and CXCL11_12
to pre-B cells transfected with human CXCR3, CXCR4, and ACKR3
at 4◦C. Under these conditions receptor endocytosis is blocked and
chemokines bind only to cell surface expressed receptors. As expected,
SupplementaryFig. 1 shows thatCXCL11bound toCXCR3andACKR3
expressing cells, but only marginally to CXCR4+ cells. Contrariwise,
CXCL12 only bound to CXCR4 and ACKR3 expressing cells. The
chimera was found to associate with ACKR3 and CXCR4 express-
ing cells and marginally to CXCR3. Binding to CXCR4 is in agree-
ment with the reported low affinity binding of CXCL12 variants with
truncated N-termini.16
The selectivity of the chimeric chemokine for ACKR3 was tested
through uptake by mouse pre-B 300.19 cells at 37◦C. The parental
cell line is known to not express either receptor. Figure 2A shows the
results obtained with cells stably expressing either human CXCR3,
CXCR4, or ACKR3. Cells were incubated with 50 nM of chemokine
labeled with Atto-565 and prior to analysis by flow cytometry any
surface bound chemokine was removed by a brief acidic wash.47
CXCR3 expressing cells selectively internalize the cognate chemokine
CXCL11, but neither the chimera nor CXCL12. Similarly, cells express-
ing CXCR4 did exclusively internalize CXCL12. By contrast, cells trans-
fected with ACKR3 internalized both chemokines and the chimera.
The findings endorse the hypothesis that ACKR3 may independently
recognize the N-terminus of CXCL11 and themain body of CXCL12.
To test a potential interaction of CXCL11_12 with ACKR1, we iso-
lated bonemarrow fromwild type andACKR1-deficientmice. Cell sus-
pensions were analyzed by flow cytometry gating for nucleated ery-
throcyte cells using transferrin (CD71) and the erythrocyte lineage
marker Ter119.58 The double positive cells from wild type animals
express high surface levels of ACKR1.44 Figure 2B shows that cells
from wild type or ACKR1-deficient animals neither bound nor inter-
nalized CXCL11_12 during incubation at 37◦C for 1 h.
To confirm the uptake of chemokines we transiently expressed
either human or mouse CXCR3, CXCR4, and ACKR3 together with
GFP in Hela cells and revealed uptake by confocal microscopy.
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F IGURE 1 Structure of engineered
CXCL11_12 H25R Gag- ybbR13. (A) The struc-
ture of CXCL11_12 was modeled onto the X-ray
structure of CXCL12 (3GV3, 1.6 A˚ resolution). (B)
Sequence alignment of human CXCL12, CXCL11,
and CXCL11_12. Cyan indicates the position of
the mutated GAG binding sites and beige the
monomer inducing H25R point mutation. The
ybbR13 sequence is marked in yellow. The circled
S in the ybbR13 sequence becomes modified by
phoshopantetheinyl transferase
Figure 3A show that Hela cells transfected with ACKR3 internal-
ized all chemokines, CXCL11, CXCL12, and the chimera. Three
dimensional rendering of image stacks reveals that the chemokines
localized to endosomal structures in the cells (Fig. 3B). By con-
trast, cells transfected with CXCR3 or CXCR4 only internalized
their cognate ligands. Taken together, our uptake data indicate that
the chimera is a selective ligand for ACKR3. Similar results were
obtained when MDCK cells were transfected with mouse ACKR3
(not shown).
We determined the affinity of the chimera for ACKR3 using com-
petition binding for CXCL11_12 labeled with Alexa647 at 4◦C, where
no receptor internalization occurs. Figure 4 shows that unlabeled
CXCL11_12 efficiently competed the binding of its fluorescent labeled
homologue. The data best fitted with a single mode binding compe-
tition curve with a dissociation constant of Kd ∼ 1 nM. The find-
ing is in agreement with previous reports, showing that binding of
chemokines to parental 300.19 cells is negligible (not shown).59,60
Similarly, CXCL11 and CXCL12 competed binding of CXCL11_12
Alexa647 with similar kinetics. Consistent with the specificity of
CXCL11 and CXCL12 for ACKR3 a highly promiscuous chemokine
CCL5, which binds several chemokine receptors namely CCR1,2,3, 51
did not compete CXCL11_12 binding.
3.3 Chemotaxis
We next tested possible effects of the chimera on CXCL11 and
CXCL12-mediated chemotaxis through their cognate receptors
CXCR3 and CXCR4, respectively. The T cell line CEMwhich expresses
high surface levels of endogenous CXCR4 was used in Boyden cham-
ber chemotaxis assays. Figure 5 depicts a typical bell-shaped dose
response curve of CEM cell chemotaxis in response to CXCL12 with a
peak migration at about 3 nM. An almost identical migratory behavior
was observed, when we performed the assay in the presence of 10 nM
CXCL11_12 in both, the upper and lower compartment, suggesting no
interference of the chimera with CXCL12 binding to CXCR4. Similarly,
we tested the chemotactic responsiveness of CXCR3-transfected
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F IGURE 2 Measurement of binding and
uptake of CXCL11_12 by FACS. (A) Pre-B
300.19 cells stably transfected with human
CXCR3 (upper row), human CXCR4 (middle
row), and human ACKR3 (bottom row) were
incubated at 37◦C for 90 min in the absence
of chemokine (control) or in the presence
of human CXCL11 (CXCL11), CXCL11_12
H25R Gag− (CXCL11_12), and human CXCL12
(CXCL12). All chemokines were labeled with
Atto565. After the incubation cells were sub-
jected to a brief acidic wash to remove surface
bound chemokines (see Methods). A typical
experiment of three independent observations
measured in duplicates is shown. (B) Bone mar-
rowwas flushed from femurs ofWT and ACKR1
KOmice. Of 12× 106 cells, eachwere incubated
with 10 nM CXCL11_12Alexa647 in RPMI at
37◦C and 5% CO2 for 1 h, then washed. Cells
were stained with antibodies against CD71 and
Ter119 to identify the erythroblast population
and analysed by flow cytometry. A typical exper-
iment of 3 independent observations measured
is shown
F IGURE 3 Uptake of CXCL11_12. (A) HeLa
cells were transiently transfected with human
(left panels) or mouse (right panels) CXCR3
(upper row), CXCR4 (middle row) and ACKR3
(bottom row). All plasmids expressed also GFP
(green) from an IRES. Cells were incubated
for 45 min with 50 nM of CXCL11_12, human
CXCL11, and human CXCL12 (red), rinsed twice
withPBS, fixedwith4%PFA, andcounterstained
with DAPI (blue). Arrowheads indicate intra-
cellular chemokines. (B) Images stacks of cells
transfected with human (left panels) or mouse
(right panels) were rendered with Imaris soft-
ware to reveal intracellular localization
pre-B 300.19 cells to CXCL11. Supplementary Fig. 2 shows the typical
bell shape curve in response to increasing concentrations of CXCL11
with a peak of chemotactic activity at 10 nM. Addition of 100 nM
chimera to the upper and lower compartment did not significantly
affect CXCL11 stimulated chemotaxis. The data further confirm that
the chimera does not interfere with CXCR3 and CXCR4-mediated
responses stimulated by their cognate ligands.
3.4 CXCL11_12 in vivo
ACKR3 is known to be expressed on vascular endothelium and to
act there as a scavenger for CXCL12,15,61 In fact systemic inhibition
of ACKR3 with small molecules leads to elevated CXCL12 serum
levels.62 Expression of ACKR3 on heart endothelium appears to have
a key role during embryonal development.15 To test our chimera in
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F IGURE 4 Competition binding of CXCL11_12 on ACKR3. Mouse
300.19 pre-B cells stably transfected with human ACKR3 were incu-
bated at 4◦C for 90 min with 1 nM CXCL11_12 labeled with Alexa647
alone (Control, □) or in the presence of increasing concentrations of
unlabeled CXCL11_12 (●), CXCL12 (▲), CXCL11 (▼), and CCL5 (𝚫).
Surface binding was measured by flow cytometry and is expressed
as geometric mean fluorescence (MFI). Blank denotes the MFI of
non-transfected mouse 300.19 pre-B cells. Normalized data from
five independentdeterminationsperformed in triplicates (CXCL11_12,
CXCL12, CXCL11). Binding of the irrelevant chemokine CCL5 was
tested in two instances with triplicates
vivo as ligand for ACKR3 we injected into reporter mice, where one
allele of ACKR3 was replaced with GFP,9 ∼ 1 𝜇mole of CXCL11_12
Alexa647. Animals were sacrificed after 20 min, hearts removed, and
fixed in PFA. Figure 6 shows a maximal projection of stacked confocal
images. The longitudinal section of the heart valve area reveals that
the fluorescent chimera specifically associated with GFP positive
endothelial cells. Three-dimensional rendering of the confocal planes
confirms internalization by GFP/ACKR3 positive cells. The chimera is
found in endosomal structures where ACKR3 is expected to deploy
CXCL11_12 for lysosomal degradation. The results also indicate that
CXCL11_12 is internalized bymouse ACKR3.
4 DISCUSSION
Specific targeting of atypical chemokine receptors is challenging due
to the promiscuity of their ligands which all bind also to at least one
canonical chemokine receptor. The two ligands of ACKR3, CXCL11,
and CXCL12, bind CXCR4 and CXCR3 respectively, induce their
internalization and are therefore not specific for ACKR3. The atypical
receptor does not couple to G-proteins and little is known about spe-
cific downstream signaling that could be used to reveal its activity in
vivo using endogenous ligands. We engineered a selective fluorescent
labeled chemokine-like ligand and show that it can be used to reveal
receptor scavenging activity in vivo.
The promiscuity and lack of ligand-induced coupling to G-proteins
suggest that atypical chemokine receptors are less sensitive than
typical receptors to alterations of the N-terminus of chemokines.
We exchanged the N-terminus of CXCL12 with the corresponding
amino acids derived from CXCL11, driven by the notion that CXCR4 is
particularly sensitive tomodifications of the N-terminus of CXCL12.16
A recent study suggests that chemokine binding and activation of
ACKR3 differs significantly from that of the typical receptors CXCR3
F IGURE 5 Effect of CXCL11_12 on CXCL12 mediated chemotaxis.
Human CEM T cells expressing endogenous CXCR4 were allowed
to migrate towards increasing concentrations of CXCL12 in mod-
ified Boyden chambers. When indicated (closed symbols) 10 nM
CXCL11_12was added to the upper and lower compartment.Migrated
cellswere counted from5randomly selectedhighpower fields (HPF) of
triplicates at 100x magnification. Typical experiment from 3 indepen-
dent mesurements
and CXCR4.36 In their study, the authors used peptides derived from
the N-termini of CXCL11 and CXCL12, to show different binding and
activation potencies depending of amino acid substitutions. However,
contrarily to our chimeric chemokine, which has comparable affinity
to ACKR3 as the natural ligands, the peptides have a markedly lower
affinity (100–2000-fold) for ACKR3.36 It is conceivable and in linewith
radiolytic footprinting analysis of CXCL12:ACKR3 complexes, that
both theN-terminus and the body constitute together the high affinity
binding to ACKR3.30
The putative GAG binding site in the rigid loop of CXCL11_12 is
most likely not involved in ACKR3 binding. The assumption is again
deduced from the radiolytic footprinting analysis of CXCL12:ACKR3
complexes where amino acids 21–26 were shown to not interact with
ACKR3.30 Hence, mutation of the GAG binding sites should reduce
the retention of the chimera on proteoglycans, without altering bind-
ing to ACKR3. Similarly, the point mutation of histidine25 to arginine,
that was reported to render CXCL12monomeric,24 should not attenu-
ate rather enhance the interactionwithACKR3,whichpreferablybinds
CXCL12monomers.27
Competition of CXCL11_12 binding to ACKR3 revealed similar
affinities for CXCL11 and CXCL12 and for the chimera itself (Fig. 4).
The data appear to contrast the uptake of the chemokines by ACKR3
expressing cells (Fig. 2), where the chimera appears to be less effi-
ciently internalized. It is plausible that chemokine uptake not only
depends on their specific affinity, but also on the possible (biased) stim-
ulatory capacity that modulates the scavenging activity.
Our FACS and microscopy analyses clearly indicate that
CXCL11_12 is a selective chemokine-like ligand which binds ACKR3
with high affinity and is readily internalized by the scavenger. These
properties render the chimeric chemokine an ideal tool to study
expression and function of the receptor. Indeed i.v. injection of
CXCL11_12 into live mice revealed its expected uptake by heart
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F IGURE 6 In vivo uptake of CXCL11_12 in mouse
heart. Longitudinal section from a mouse heart.
Upper panels maximal projections of 135 stacks.
Arrows on the red panel indicate CXCL11_12 posi-
tive endosomal structures. Endogenous GFP (green)
demarks ACKR3positive cells andDAPI (blue) nuclei.
Bottom row shows three-dimensional rendering of
the 135 stacks at 2 electronic magnifications. Colors
as in the upper panels. Images were taken at 0.29 𝜇m
distance with a 63× oil immersion objective
endothelium. This makes the chimera a particularly useful reagent
for in vivo studies that is superior to the use of mouse monoclonal
antibodies29 which would interact with endogenous Fc-receptors. As
long as specific high affinity antibodies either from different species
or as Fab’2 are not available the chimera remains an easily accessible
alternative to study ACKR3 function. The high sequence homol-
ogy between human and mouse CXCL12, with only 1 conservative
substitution in the CXCL12-derived domain, and only 2 alterations
in the sequence part derived from CXCL11 (proline2/leucine and
lysine6/glutamine human/mouse, respectively) may explain the reac-
tivity of our CXCL11_12 with ACKR3 from both species. The cross
reactivity between species allows to use the chimera to determine
the scavenging activity of ACKR3 in mice in the absence of functional
antibodies. The finding that CXCL11_12 does not interfere with
CXCL11 and CXCL12 signaling through their cognate receptors fur-
ther suggest its application in complex biological systems. It remains
to be established if a similar strategy can be used to engineer selective
ligands for other atypical receptors like ACKR4, which binds CCL19,
CCL21 (CCR7), and CCL25 (CCR9).
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